:: CLDF ::

Home | Contact Us | Bookmark

NASH

HCC

ALCOHOL LIVER DISEASE

PEDIATRIC LIVER DISEASE

Embassy of Education

Slide Library Webcasts Abstract Library LiverQ Academy National Conference

Drug & Device Development

Available Topics

11-24-2014	Obeticholic acid promising against NASH liver damage
11-20-2014	Drug spending tops $1 trln on hepatitis C, cancer therapies -study
11-11-2014	Interferon-free regimen works against HCV in liver recipients
11-11-2014	AbbVie, Enanta drug shows potential in hep C genotype 4 patients
11-10-2014	INSIGHT-After hep C cure, companies target next big liver disease market
11-03-2014	Sofosbuvir-ledipasvir effective for relapsed HCV-1
09-30-2014	France uses tax to put pressure on hepatitis C drug prices
09-22-2014	Smartphone app may allow parents to screen newborns for jaundice
09-17-2014	Gilead's pancreas cancer drug fails mid-stage study
09-03-2014	Triptolide nanoformulation targets liver cancer cells
08-27-2014	ANALYSIS-InterMune drug may offer big upside to Roche if aimed at liver
08-15-2014	Achillion's hepatitis C drug cures all patients in mid-stage trial
08-12-2014	Intercept drug for non-alcoholic steatohepatitis found effective
08-06-2014	High HCV response rates with daclatasvir/asunaprevir: phase III data
07-23-2014	Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter
07-16-2014	Lanreotide slows progression of neuroendocrine tumors
07-11-2014	Senators ask Gilead to explain cost of Sovaldi hepatitis drug
07-07-2014	Japan approves all-oral hepatitis C dual drug regimen
06-17-2014	AbbVie all-oral hepatitis C therapy gets rapid EU review
06-13-2014	AbbVie says hepatitis C regimen gets nod for FDA priority review
06-11-2014	Lilly's Cyramza fails in liver cancer trial
05-16-2014	Drug for alpha-1 antitrypsin deficiency fails key trial
04-22-2014	Drug combination shows more efficacy against hepatitis C
04-14-2014	Drug for primary biliary cirrhosis proves highly effective in study
04-11-2014	Doctors welcome hepatitis C drug rivals
04-10-2014	Bristol-Myers hepatitis C treatment cures up to 90%: study
03-20-2014	Geron says FDA halts patient enrollment in another cancer trial
03-17-2014	Primary biliary cirrhosis drug effective in third late-stage trial
03-11-2014	Bayer's Nexavar misses target in liver cancer trial
03-04-2014	Dynavax withdraws EU marketing application for Hep B vaccine
03-04-2014	Panel favors continuation of tivantinib study for liver cancer
03-04-2014	Drug for nonalcoholic steatosis meets main goal in study
12-18-2013	Stellar hepatitis C data puts Gilead farther ahead of pack
12-10-2013	AbbVie says most in hepatitis C study show improvement

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2023 GI Fellow Board of Advisors

Other Resources

Journal Abstracts
Hep C Link to Care

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.

Subscribe